Sign In
Buy DXCM
$72.77
-0.680 (-0.93%)
At Close: Jun 03, 2026
Got $200? 2 Healthcare Stocks to Buy and Hold Forever
04:32am, Wednesday, 26'th Feb 2025
Healthcare is considered a defensive industry, since good medical care is needed regardless of economic or market conditions. Therefore many companies in this sector are somewhat insulated from the im
Quality Key in Volatile Market, NFLX & DXCM Value Plays
03:48pm, Friday, 21'st Feb 2025
Friday's trading session showed weakness is possible in the current market, and Lisa Schreiber says investors need to turn to quality in a time of volatility. Lisa expects the U.S. economy to bolster
4 Seniors & Aging Demographics Stocks to Watch Right Now
12:10pm, Friday, 21'st Feb 2025
ABBV, AMGN, SYK and DXCM are well-poised to benefit from the evolving new opportunities in Seniors & Aging Demographics within healthcare.
NVIDIA's Rise Puts These 3 Healthcare Stocks in the Spotlight
01:36pm, Tuesday, 18'th Feb 2025
ILMN, IQV and DXCM are leveraging AI advancements to drive innovation in genomics, clinical research and diabetes management.
Analyst Cautiously Optimistic On DexCom As Competitive Pressures Loom
03:04pm, Friday, 14'th Feb 2025
On Thursday, Dexcom, Inc.'s DXCM fourth-quarter revenue rose 8% year-over-year to $1.114 billion, beating the analyst consensus estimate of $1.104 billion.
DexCom Analysts Increase Their Forecasts After Q4 Earnings
09:22am, Friday, 14'th Feb 2025
DexCom, Inc. DXCM reported weaker-than-expected earnings for its fourth quarter on Thursday.
DexCom Stock Rises Despite Q4 Earnings Miss & Lower Margins
07:56am, Friday, 14'th Feb 2025
DXCM's fourth-quarter 2024 earnings decline despite increasing sales. Its performance in 2025 is expected to be fueled by global growth in CGM adoption, strong Sensor sales and expansion into new mark
DexCom, Inc. (DXCM) Q4 2024 Earnings Call Transcript
09:33pm, Thursday, 13'th Feb 2025
DexCom, Inc. (NASDAQ:DXCM ) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Sean Christensen - Vice President of Finance and Investor Relations Kevin Sayer - Chairma
DexCom: Revenue Up, EPS Misses Mark
07:02pm, Thursday, 13'th Feb 2025
DexCom (DXCM 0.26%), known for its continuous glucose monitoring (CGM) systems, recently unveiled its Q4 2024 earnings report on Feb. 13, 2025. This release highlighted an 8% growth in revenue, which
Here's What Key Metrics Tell Us About DexCom (DXCM) Q4 Earnings
06:30pm, Thursday, 13'th Feb 2025
The headline numbers for DexCom (DXCM) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estima
DexCom (DXCM) Misses Q4 Earnings Estimates
06:15pm, Thursday, 13'th Feb 2025
DexCom (DXCM) came out with quarterly earnings of $0.45 per share, missing the Zacks Consensus Estimate of $0.50 per share. This compares to earnings of $0.50 per share a year ago.
Dexcom beats fourth-quarter sales, reiterates 2025 revenue forecast
05:09pm, Thursday, 13'th Feb 2025
Medical device maker Dexcom beat fourth-quarter sales estimates helped by resilient demand for its continuous glucose monitors (CGMs) used by patients with diabetes.
Dexcom Tumbles As Fourth-Quarter Profit Lags Expectations
04:12pm, Thursday, 13'th Feb 2025
Dexcom stock fell late Thursday after the company missed fourth-quarter profit expectations by a nickel per share. The post Dexcom Tumbles As Fourth-Quarter Profit Lags Expectations appeared first on
DXCM Q4 Earnings to Reflect Market Expansion & Stelo Impact?
07:21am, Tuesday, 11'th Feb 2025
DexCom Q4 results are likely to reflect strong growth on the back of U.S. sales expansion, global gains and Stelo traction, driving momentum and market expansion into 2025.
Countdown to DexCom (DXCM) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
10:21am, Monday, 10'th Feb 2025
Evaluate the expected performance of DexCom (DXCM) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics
